Orum Therapeutics, a biotechnology company preparing for its KOSDAQ listing, announced its goal to achieve sales of KRW 93 billion (USD 69.9 million) by 2026. In a media conference call held on the…

There is an evaluation that Samsung Biologics' stock could rise in the short term if the U.S. Biosecurity Law is passed. On the 7th, Kim Jun-young of Meritz Securities stated, “Samsung Biologics is a…

Celltrion has officially entered the ASEAN market by establishing a local subsidiary in Vietnam. Following the company's tradition of having its top executives spearhead entry into key markets,…

Celltrion announced on the 27th that it has launched a media campaign in the U.S. for "Zymfentra," the world’s only infliximab subcutaneous (SC) formulation for treating autoimmune diseases. The…

HK inno.N's novel drug for gastroesophageal reflux disease (GERD), K-CAB, has received marketing approval in Malaysia. HK inno.N announced on the 26th that K-CAB tablets (ingredient: Tegoprazan) were…

Samsung Biologics announced on the 25th that it has introduced two new Contract Development Organization (CDO) platforms at the ‘2024 Bio Process International (BPI)’ conference, a global bio…

The government has selected the ‘Korea Value Up’ Index as part of its efforts to address the Korea Discount, and 12 stocks from the healthcare sector have been included in the index. On the 24th,…

Lunit, a leading medical AI company focused on developing solutions that extend beyond diagnosis into treatment, is expected to see a steady increase in corporate value, according to industry…

Yuhan Corporation announced on the 11th that it will receive $60 million (approximately 80 billion KRW) in commercialization royalties for its non-small cell lung cancer treatment "lazertinib"…

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the Phase 2 clinical trial of "NLY01," a new drug candidate being developed by D&D…